Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Blackhawk Growth Corp C.BLR.WT


Primary Symbol: C.BLR Alternate Symbol(s):  BLRZF

Blackhawk Growth Corp. is a Canada-based investment holding company. The Company invests in equity and debt instruments of companies to generate positive returns for shareholders. It focuses on investing in multiple companies across a variety of sectors across North America. The Company has focused its investments on the health, cannabis and cannabidiol (CBD) industries, in both Canada and the United States.


CSE:BLR - Post by User

Comment by moneywinner1on Nov 09, 2020 11:38am
181 Views
Post# 31863057

RE:Blackhawk Submits SARS-CoV-2 IgG / IgM Rapid Test Kit

RE:Blackhawk Submits SARS-CoV-2 IgG / IgM Rapid Test Kit

Vancouver, British Columbia - TheNewswire - November 9, 2020 - Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (the "Corporation" or "Blackhawk"), is pleased to provide the following corporate update.

The Health Canada Interim Order ("IO") application was completed and submitted for its SARS-CoV-2 IgG / IgM Rapid Test Kit. 

The extensive application was submitted November 4th and Health Canada confirmed receipt of the application the same day.

Even though Blackhawk cannot guarantee timelines, the anticipated time to process the application is between 40 and 60 days.

The SARS-CoV-2 IgG / IgM Rapid Test Kit currently holds Federal Drug Administration (FDA) Emergency Use Authorization (EUA) as well as a CE Mark in Europe. 

https://www.thenewswire.com/press-releases/1LYzFPdZ7-blackhawk-submits-sars-cov-2-igg-igm-rapid-test-kit-interim-order-application-and-provides-update-on-previously-submitted-exprobe-sars-cov-2-testing-kit.html

<< Previous
Bullboard Posts
Next >>